Latest. Johnson & Johnson announced on Monday that it has entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, with potential regulatory and commercial milestone payments of up to approximately $1.125 billion, for a total of up to about $3.3 billion. The transaction is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions. Under a separate agreement contingent on the close, Blackstone Life Sciences will pay Johnson & Johnson a total of $750 million over multiple years to fully fund the Phase 3 development of Ollin’s lead drug, OLN324, in return for certain regulatory and sales milestone payments and single digit royalties.
OLN324 is a Phase 3 investigational bispecific antibody targeting VEGF and angiopoietin-2, two pathways in retinal diseases, being developed for wet age related macular degeneration and diabetic macular edema, which Johnson & Johnson said together affect more than 40 million people worldwide. BioPharma Dive noted the drug would compete with Roche’s Vabysmo in a crowded retinal market, and that an RBC Capital Markets analyst called the price high relative to competitors while calling the deal a logical strategic fit with J&J’s eye care business.
Johnson & Johnson is in advanced talks to buy Ollin Biosciences for up to $3.4 billion, the Financial Times reported on Sunday, citing people familiar with the matter. The structure under discussion is $2.2 billion in upfront cash and up to $1.2 billion in milestone payments, and the report said the discussions could still fall apart.
Ollin, backed by Arch Venture Partners and Mubadala Capital, is developing OLN324 for wet age related macular degeneration and diabetic macular oedema, two leading causes of severe vision loss, and the treatment is expected to enter late stage clinical trials. Neither company commented in the report.